ReviewCancers2017
ALK in Non-Small Cell Lung Cancer (NSCLC) Pathobiology, Epidemiology, Detection from Tumor Tissue and Algorithm Diagnosis in a Daily Practice.
Review in Cancers, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed.
- Cost of managing brain metastases in patients with ALK+ advanced NSCLC with first-line tyrosine kinase inhibitors in the UK.Lung cancer management · 2026Article
- Beyond EML4: efficacy of targeted therapy in lung cancer patients with rare ALK fusions - a real-world retrospective analysis.NPJ precision oncology · 2026Article
- Clinical and molecular characterization of a large Brazilian lung cancer cohort: a real-world observational study.Lancet regional health. Americas · 2026Article
- Outcome of Metastatic Biliary Tract Cancer HarbouringJournal of clinical medicine · 2025Article
- Remarkable tumor response to Iruplinalkib in a 14-year-old girl withFrontiers in oncology · 2025Article
- Locally advanced/metastatic non-small-cell lung cancer in Lebanon: focus on ALK tyrosine kinase inhibitors.Future oncology (London, England) · 2025Review
- Cytomorphological and histomorphological features of lung adenocarcinoma with epidermal growth factor receptor mutation and anaplastic lymphoma kinase gene rearrangement.Oncology letters · 2025Article
- A Review on Anaplastic Lymphoma Kinase (ALK) Rearrangements and Mutations: Implications for Gastric Carcinogenesis and Target Therapy.Current protein & peptide science · 2024Review
- Clinical Relevance of Targeted Therapy and Immune-Checkpoint Inhibition in Lung Cancer.Pharmaceutics · 2023Review
- Two case reports: EML4-ALK rearrangement large cell neuroendocrine carcinoma and literature review.Frontiers in oncology · 2023Article
- Review
- [Molecule pathology in the treatment of lung cancer-Interdisciplinary view of the importance in thoracic surgery].Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen · 2022Review
- Article
- Real-World Data on the Prevalence of Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer in the Middle East and North Africa.JCO global oncology · 2021Article
- Efficacy of Incremental Next-Generation ALK Inhibitor Treatment in Oncogene-Addicted,Journal of personalized medicine · 2020Article
- [Pharmacology and Clinical Evaluation of Ensartinib Hydrochloride Capsule].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2020Review
- Inconsistent Intersample ALK FISH Results in Patients with Lung Cancer: Analysis of Potential Causes.Cancers · 2020Article
- Care of patients with non-small-cell lung cancer stage III - the Central European real-world experience.Radiology and oncology · 2020Observational
- Intellectual Structure and Evolutionary Trends of Precision Medicine Research: Coword Analysis.JMIR medical informatics · 2020Article
- Oncogene addiction and tumor mutational burden in non-small-cell lung cancer: Clinical significance and limitations.Thoracic cancer · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Patients with advanced-stage non-small cell lung carcinoma (NSCLC) harboring an ALK rearrangement, detected from a tissue sample, can benefit from targeted ALK inhibitor treatment. Several increasingly effective ALK inhibitors are now available for treatment of patients. However, despite an initial favorable response to treatment, in most cases relapse or progression occurs due to resistance mechanisms mainly caused by mutations in the tyrosine kinase domain of ALK. The detection of an ALK rearrangement is pivotal and can be done using different methods, which have variable sensitivity and specificity depending, in particular, on the quality and quantity of the patient's sample. This review will first highlight briefly some information regarding the pathobiology of an ALK rearrangement and the epidemiology of patients harboring this genomic alteration. The different methods used to detect an ALK rearrangement as well as their advantages and disadvantages will then be examined and algorithms proposed for detection in daily routine practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.